Joerg Pfirrmann - Sartorius Stedim Executive
| SDMHF Stock | USD 214.00 11.35 5.04% |
Executive
Joerg Pfirrmann is Member of the Executive Committee - Finance, Information Technology, Human Resources of Sartorius Stedim Biotech
| Age | 43 |
| Phone | 33 4 42 84 56 00 |
| Web | https://www.sartorius.com |
Sartorius Stedim Management Efficiency
The company has return on total asset (ROA) of 0.1389 % which means that it generated a profit of $0.1389 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.3306 %, meaning that it generated $0.3306 on every $100 dollars invested by stockholders. Sartorius Stedim's management efficiency ratios could be used to measure how well Sartorius Stedim manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 12 records | EXECUTIVE Age | ||
| Ben Scheu | Sharps Technology | N/A | |
| Brian Koopman | Utah Medical Products | 54 | |
| Mark Fox | Utah Medical Products | N/A | |
| James Thrower | GlucoTrack | 54 | |
| Juan DiazCartelle | Microbot Medical | 48 | |
| Drinda Benjamin | GlucoTrack | 48 | |
| Paul Goode | GlucoTrack | 55 | |
| James Cardwell | GlucoTrack | 63 | |
| Ekene Ofodile | Innovative Eyewear | N/A | |
| Jaoquin Abondano | Innovative Eyewear | 40 | |
| Marcena Clawson | Utah Medical Products | N/A | |
| Mark Tapsak | GlucoTrack | 55 | |
Management Performance
| Return On Equity | 0.33 | |||
| Return On Asset | 0.14 |
Sartorius Stedim Biotech Leadership Team
Elected by the shareholders, the Sartorius Stedim's board of directors comprises two types of representatives: Sartorius Stedim inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sartorius. The board's role is to monitor Sartorius Stedim's management team and ensure that shareholders' interests are well served. Sartorius Stedim's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sartorius Stedim's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Andreas Theisen, Director of Investor Relations | ||
| Reinhard Vogt, Executive VP of Marketing Sales and Services and Director | ||
| AnneMarie Graffin, Non-Executive Independent Director | ||
| Petra Kirchhoff, Vice President of Corporate Communications and Investor Relations | ||
| Henri Riey, Non-Executive Independent Director | ||
| Michael Melingo, Deputy CEO - Marketing, Services and Business Development | ||
| OscarWerner Reif, Deputy CEO - Research and Development, Member of the Executive Committee and Executive Director | ||
| Olivier Guitard, Head BPS | ||
| Joachim Kreuzburg, Chairman of The Board and CEO | ||
| Volker Niebel, Executive VP of Operations and IT and Director | ||
| Bernard Lemaitre, Non-Executive Director | ||
| Susan Dexter, Non-Executive Independent Director | ||
| Heiko Imhl, VP Relations | ||
| Arnold Picot, Chairman of Supervisory Board, Member of The Admin. Board, Non Executive Director, Chairman of Remuneration Committee and Member of Audit Committee | ||
| Lothar Kappich, Director | ||
| Joerg Pfirrmann, Member of the Executive Committee - Finance, Information Technology, Human Resources | ||
| Benedikt Orzelek, Investor Relations Contact | ||
| John Mackay, Sales Marketing | ||
| Liliane Lassus, Non-Executive Director |
Sartorius Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Sartorius Stedim a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.33 | |||
| Return On Asset | 0.14 | |||
| Profit Margin | 0.20 % | |||
| Operating Margin | 0.30 % | |||
| Current Valuation | 32.97 B | |||
| Shares Outstanding | 92.17 M | |||
| Shares Owned By Insiders | 73.81 % | |||
| Shares Owned By Institutions | 13.73 % | |||
| Price To Earning | 60.34 X | |||
| Price To Book | 13.58 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Sartorius Stedim in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Sartorius Stedim's short interest history, or implied volatility extrapolated from Sartorius Stedim options trading.
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sartorius Stedim Biotech. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in rate. Note that the Sartorius Stedim Biotech information on this page should be used as a complementary analysis to other Sartorius Stedim's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Complementary Tools for Sartorius Pink Sheet analysis
When running Sartorius Stedim's price analysis, check to measure Sartorius Stedim's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sartorius Stedim is operating at the current time. Most of Sartorius Stedim's value examination focuses on studying past and present price action to predict the probability of Sartorius Stedim's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sartorius Stedim's price. Additionally, you may evaluate how the addition of Sartorius Stedim to your portfolios can decrease your overall portfolio volatility.
| CEOs Directory Screen CEOs from public companies around the world | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation |